Clearmind Successfully Completes Patient Recruitment for the First Alcohol Use Disorder Cohort of its CMND-100 Phase I/IIa Clinical Trial
Clearmind Medicine completed patient recruitment for the first Alcohol Use Disorder cohort of its CMND-100 Phase I/IIa trial, marking its first evaluation of the drug in diagnosed AUD patients. Part B consists of two sequential single-dose ascending cohorts (80 mg and 160 mg) of six patients each, assessing safety, tolerability, pharmacokinetics, and early signals of efficacy such as reduced alcohol craving.
Key figures
- Drug Name
- CMND-100
- Phase Of Trial
- Phase I/IIa
- Cohort doses
- ["80 mg","160 mg"]
- Granted patents
- 32
- Patients per cohort
- 6
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.